Meeting
2020 ASCO Virtual Scientific Program
An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.
Authors
Yoon-Koo Kang
Asan Medical Center, Seoul, South Korea
Yoon-Koo Kang , Kensei Yamaguchi , Do-Youn Oh , Shunsuke Kondo , Yasutoshi Kuboki , Manabu Morimoto , Hiroki Hara , Sun Young Rha , Chia-Chi Lin , Yoshifumi Tachibana , Miaomiao Ge , Mabrouk M. Elgadi , Shigehisa Kitano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03433898
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3054)
DOI
10.1200/JCO.2020.38.15_suppl.3054
Abstract #
3054
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer.
First Author: Kensei Yamaguchi
Poster
2020 ASCO Virtual Scientific Program
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
First Author: Thorsten Oliver Goetze
Poster
2019 ASCO Annual Meeting
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
First Author: Manish R. Patel
Poster
2014 ASCO Annual Meeting
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
First Author: Christopher Ryan Heery